Zobrazeno 1 - 10
of 509
pro vyhledávání: '"potassium-competitive acid blocker"'
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract The management of eosinophilic esophagitis (EoE) has not been completely established yet. There is a controversy over the universal maintenance therapy for EoE to prevent esophageal fibrostenotic complications. Using an employer-based insura
Externí odkaz:
https://doaj.org/article/e071471172a94eb3962743afa05b71b9
Autor:
Tomoyo Iwano, Tsutomu Takeda, Shotaro Oki, Yasuko Uemura, Momoko Yamamoto, Ryota Uchida, Hisanori Utsunomiya, Daiki Abe, Nobuyuki Suzuki, Atsushi Ikeda, Yoichi Akazawa, Kumiko Ueda, Hiroya Ueyama, Mariko Hojo, Akihito Nagahara
Publikováno v:
Case Reports in Gastroenterology, Vol 18, Iss 1, Pp 386-394 (2024)
Introduction: In recent years, the frequency of idiopathic peptic ulcers (IPUs) has increased. However, the clinicopathological characteristics of IPU have not been fully elucidated and treatment methods for recurrent and refractory cases have not ye
Externí odkaz:
https://doaj.org/article/6cae3afd903c42f29e68af6b43a7b457
Publikováno v:
Clinical Endoscopy, Vol 57, Iss 4, Pp 417-423 (2024)
Since the introduction of vonoprazan, a potassium-competitive acid blocker (P-CAB), it has been demonstrated to reversibly inhibit gastric acid secretion by engaging in potassium-competitive ionic binding to H+/K+-ATPase. In contrast, proton pump inh
Externí odkaz:
https://doaj.org/article/b4e6fcd031d0415a9bc70403e5fb2236
Publikováno v:
The Korean Journal of Helicobacter and Upper Gastrointestinal Research, Vol 24, Iss 2, Pp 157-167 (2024)
Objectives Associated factors for the failure of Helicobacter pylori (HP) eradication have been evaluated in many studies; however, the different study population of previous studies prevents us from understanding the comparative risk between factors
Externí odkaz:
https://doaj.org/article/9418389d18c9417d8100b3ac0624b53a
Autor:
Yuji Urabe, Hideki Ishikawa, Akira Ishikawa, Shingo Ishiguro, Kazuki Ishibashi, Koji Arihiro, Michihiro Mutoh, Shiro Oka
Publikováno v:
Case Reports in Gastroenterology, Vol 18, Iss 1, Pp 293-298 (2024)
Introduction: Familial adenomatous polyposis (FAP), a hereditary disorder of the gastrointestinal tract, is an autosomal dominant inherited condition caused by germline mutations in the adenomatous polyposis coli (APC) gene. It is characterized by th
Externí odkaz:
https://doaj.org/article/47528158d32949ff9e145062caa6a565
Publikováno v:
Trials, Vol 24, Iss 1, Pp 1-13 (2023)
Abstract Background Vonoprazan results in more potent acid suppression for gastroesophageal reflux disease (GERD) than proton pump inhibitors. It has only been approved for treating erosive esophagitis in China, but 30–40% of GERD patients cannot a
Externí odkaz:
https://doaj.org/article/dd87100929684a2eb7a8859acc8ce406
Autor:
Gwang Ha Kim, Myung-Gyu Choi, Jin Il Kim, Soo Teik Lee, Hoon Jai Chun, Kook Lae Lee, Suk Chei Choi, Jae-Young Jang, Yong Chan Lee, Jae Gyu Kim, Ki Bae Kim, Ki-Nam Shim, Chong Il Sohn, Sung Kook Kim, Sang Gyun Kim, Jin Seok Jang, Nayoung Kim, Hwoon-Yong Jung, Hyojin Park, Kyu Chan Huh, Kwang Jae Lee, Su Jin Hong, Song Baek, Jin Joo Han, Oh Young Lee
Publikováno v:
Gut and Liver, Vol 17, Iss 6, Pp 884-893 (2023)
Background/Aims: Fexuprazan is a novel potassium-competitive acid blocker that could be of benefit to patients with gastric mucosal injury. The aim of this study was to assess the 2-week efficacy and safety of fexuprazan in patients with acute or chr
Externí odkaz:
https://doaj.org/article/3e73160ecc0e4882b0041d06473c3977
Autor:
Jong Kyu Park
Publikováno v:
The Korean Journal of Helicobacter and Upper Gastrointestinal Research, Vol 23, Iss 3, Pp 180-187 (2023)
A variety of proton pump inhibitors (PPIs) have been developed in Korea since the introduction of omeprazole (the first PPI) in 1989. PPIs have served as the basic therapeutic approach for the management of gastric acid-related diseases for 30 years
Externí odkaz:
https://doaj.org/article/285976734dc94601990a93ebcfc04d86
Autor:
Mun Young Cho, Yu Kyung Cho
Publikováno v:
The Korean Journal of Helicobacter and Upper Gastrointestinal Research, Vol 23, Iss 3, Pp 167-173 (2023)
Owing to their superior pharmacokinetic and pharmacodynamic profiles, potassium-competitive acid blockers (P-CABs) score over proton pump inhibitors (PPIs) in the treatment of gastric acid-related disorders and may provide clinical benefit in the man
Externí odkaz:
https://doaj.org/article/e5d8afb3bca54c2da599d0bb768c46ad
Autor:
Daniel M Simadibrata, Elvira Lesmana, Muhammad I A Pratama, Adrianus J Sugiharta, Afiah S Winarizal, Yeong Y Lee, Ari F Syam
Publikováno v:
JGH Open, Vol 8, Iss 3, Pp n/a-n/a (2024)
Abstract Introduction Proton pump inhibitor (PPI) is the mainstay therapy for the maintenance of healed erosive esophagitis (EE). It is unknown whether potassium‐competitive acid blockers (PCABs) are more efficacious and safer than PPIs. Methods On
Externí odkaz:
https://doaj.org/article/4da4fcf3c1fd4330a182c8c22c452cec